Immediate Impact
25 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Pancreatic cancer
2025 Standout
Works of Daniel Campbell being referenced
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial
2020
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Daniel Campbell | 327 | 27 | 28 | 30 | 29 | 14 | 357 | |
| Seth Walker | 355 | 34 | 10 | 19 | 31 | 11 | 385 | |
| Jill M. VanDalfsen | 296 | 15 | 13 | 31 | 33 | 11 | 313 | |
| Marina Litvin | 198 | 7 | 71 | 54 | 32 | 12 | 329 | |
| Richard R. Dooley | 244 | 13 | 85 | 44 | 53 | 14 | 340 | |
| R. Michl | 236 | 3 | 51 | 48 | 24 | 16 | 333 | |
| S. Bertasi | 234 | 4 | 113 | 39 | 30 | 17 | 312 | |
| J McGaw | 199 | 4 | 40 | 17 | 85 | 16 | 352 | |
| G Borgo | 341 | 6 | 55 | 25 | 34 | 19 | 412 | |
| Jonathan Malka-Rais | 227 | 8 | 26 | 15 | 10 | 11 | 345 | |
| Neil Mulrooney | 204 | 4 | 100 | 15 | 83 | 13 | 326 |
All Works
Loading papers...